Singapore's Aslan Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Focused on in-licensing early-stage compounds to take advantage of efficiencies of running trials in Asia, Aslan previously obtained a HER2/EGFR inhibitor from Array BioPharma.